Overdosage of combination hormonal contraceptives may cause nausea, vomiting, vaginal bleeding, or other menstrual irregularities. Given the nature and design of NuvaRing® (etonogestrel, ethinyl estradiol vaginal ring) it is unlikely that overdosage will occur. If NuvaRing® (etonogestrel, ethinyl estradiol vaginal ring) is broken, it does not release a higher dose of hormones. Serious ill effects have not been reported following acute ingestion of large doses of oral contraceptives by young children. There are no antidotes and further treatment should be symptomatic.

NuvaRing® (etonogestrel, ethinyl estradiol vaginal ring) should notbeusedinwomen who currently have the following conditions:

• Thrombophlebitis or thromboembolic disorders
• A past history of deep vein thrombophlebitis or thromboembolic disorders
• Cerebral vascular or coronary artery disease (current or history)
• Valvular heart disease with thrombogenic complications
• Severe hypertension
• Diabetes with vascular involvement
• Headaches with focal neurological symptoms
• Major surgery with prolonged immobilization
• Known or suspected carcinoma of the breast or personal history of breast cancer
• Carcinoma of the endometrium or other known or suspected estrogen-dependent neoplasia
• Undiagnosed abnormal genital bleeding
• Cholestatic jaundice of pregnancy or jaundice with prior hormonal contraceptive use
• Hepatic tumors (benign or malignant) or active liver disease
• Known or suspected pregnancy
• Heavy smoking ( ≥ 15 cigarettes per day) and over age 35
• Hypersensitivity to any of the components of NuvaRing® (etonogestrel, ethinyl estradiol vaginal ring)

Last reviewed on RxList: 7/10/2009
This monograph has been modified to include the generic and brand name in many instances.